The latest price target for MEI Pharma (NASDAQ:MEIP) was reported by Laidlaw & Co. on July 23, 2024. The analyst firm set a price target for $0.00 expecting MEIP to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for MEI Pharma (NASDAQ:MEIP) was provided by Laidlaw & Co., and MEI Pharma downgraded their hold rating.

There is no last upgrade for MEI Pharma

The last downgrade for MEI Pharma Inc happened on July 23, 2024 when Laidlaw & Co. changed their price target from N/A to N/A for MEI Pharma Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MEI Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MEI Pharma was filed on July 23, 2024 so you should expect the next rating to be made available sometime around July 23, 2025.

While ratings are subjective and will change, the latest MEI Pharma (MEIP) rating was a downgraded with a price target of $0.00 to $0.00. The current price MEI Pharma (MEIP) is trading at is $2.70, which is out of the analyst’s predicted range.